No, they do not. To date, the only reported data for EDP-305 are preclinical. Moreover, NASH—unlike HCV—is a multifaceted disease where the MoAs of the various drug classes being tested are poorly understood by comparison to the DAAs for HCV.
Regarding FXR agonists specifically, I don't consider ICPT's results in the phase-2 FLINT study to be full-fledged validation of this MoA for treating NASH.
In short, the investing theme described in my prior post doesn’t apply to NASH.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.